Skip to content

Septerna, Inc. SEPN Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Amgen logo
AmgenAMGN
-$959M-9.7%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$4.12M-40.6%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$3.49M-1,155%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
-$43.4M-60.1%
Precigen logo
PrecigenPGEN
-$2.27M-289%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
-$9.21M-261%

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Cash & equivalents$71.6M-65.9%
Total debt$23.1M-7.7%
Total equity$378.5M+195%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.62B+319%

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Return on equity-12.2%
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Reported directly by Septerna, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: Septerna, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Septerna, Inc.'s change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Septerna, Inc.'s change in accrued liabilities?
Septerna, Inc. (SEPN) reported change in accrued liabilities of -$3.53M in Q1 2026.
How has Septerna, Inc.'s change in accrued liabilities changed year-over-year?
Septerna, Inc.'s change in accrued liabilities decreased by 2.5% year-over-year, from -$3.45M to -$3.53M.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.